

Advanced breast cancer: diagnosis and management (Partial update)

Date: 06/06/2025

Location: Virtual

Minutes: FINAL

Committee members present:

Adam Firth	Chair	Present for notes 1 - 9
Ramsey Cutress	Topic Adviser	Present for notes 1 - 9
Mark Davies	Medical oncologist	Present for notes 6 - 9
Milly Finch	Pharmacist	Present for notes 1 - 9
Karen Lockwood	Lay member	Present for notes 1 - 9
Simon Lowes	Radiologist	Present for notes 1 - 9
Madeleine Meynell	Lay member	Present for notes 1 - 9
Mitesh Naik	Radiologist	Present for notes 6 - 9
Tim Robinson	Medical oncologist	Present for notes 1 - 7
Clare Sacco	Lay member	Present for notes 1 - 9
Ben Thwaites	Pharmacist	Present for notes 1 - 9

In attendance:

Adefisayo Abba-Abba	Technical Analyst	Present for notes 6 - 9
Olivia Crane	Senior Technical Analyst	Present for notes 1 - 9
Gareth Haman	Senior Guidance Content Designer	Present for notes 1 - 9
Marie Harrisingh	Topic Lead	Present for notes 1 - 9
James Hawkins	Health Economics Adviser	Present for notes 1 - 9
Tzujung Lai	Health Economist	Present for notes 1 - 9
Yolanda Martinez	Technical Analyst	Present for notes 1 - 9
Adam O'Keefe	Project Manager	Present for notes 1 - 9
Katherine Saxby	Medicines Adviser	Present for notes 1 - 5

Apologies:

Elinor Sawyer	Clinical oncologist
Caroline Tweedie	Clinical Nurse Specialist
Andrea Heath	Senior Information Specialist, NICE

1. Welcome, introductions and apologies

The Chair welcomed the committee members and NICE attendees to the third committee meeting for the partial update to the NICE Advanced breast cancer: diagnosis and management guideline.

The Chair informed the Committee that apologies had been received. These are noted above.

2. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Advanced breast cancer.

The Chair asked committee members to verbally declare any new interests, the following new interests were declared:

Name	Declaration	Date DOI arose	Action
Ramsey Cutress	Co-applicant on an academic led outline stage 1 application to the NIHR HTA for a clinical trial proposal to test if axillary surgery (sentinel node biopsy) can be omitted in certain lower risk groups.	Jun 2025	Non-specific. Declare and participate.
Mark Davies	Fee paid to attend advisory board inavolisib, a potential new drug for metastatic breast cancer. Role was to discuss clinical trial data.	Apr 2025	Non-specific. Declare and participate.

The Chair and a senior member of the Developer's team noted that neither this interest nor any previously declared interests would prevent attendees from fully participating in the meeting.

3. Minutes of the previous meeting

The minutes of the previous meeting were ratified as an accurate record.

4. Review Question 1.1: What is the clinical and cost effectiveness of a platinum-containing chemotherapy regimen compared to a non-platinum-containing chemotherapy regimen in people with advanced:
• **triple negative breast cancer?**

• breast cancer of any receptor sub-type with BRCA germline mutations?
The Chair introduced Technical Analyst Yolanda Martinez, who presented the clinical evidence identified for the Review Question. James Hawkins, who explained that no cost-effectiveness evidence had been identified. The committee discussed the evidence presented, asked questions and discussed inequalities considerations before drafting recommendations.
5. Plans for chemotherapy section of Guideline
The Chair introduced NICE Senior Technical Analyst Olivia Crane, who sought the committee's input on the draft review protocol for the planned Review Question on monitoring response to treatment and disease progression of metastatic breast cancer using PET-CT.
6. Revisit Review protocol for Review Question 2
The Chair introduced Adefisayo Abba-Abba, Technical Analyst, who revisited the Review protocol for Review Question 2 with the committee, to seek further committee input and finalise.
7. Health economics modelling discussion (reviews 2 and 3)
James Hawkins and Tzujung Lai, Health Economist updated the committee on, and discussed with it, plans for health economic modelling to inform the guideline update.
8. Further discussion on Review protocol 3 for monitoring response to treatment and disease progression of metastatic breast cancer using PET-CT
Olivia Crane, Senior Technical Analyst, concluded with the committee discussion on the Review Protocol for Monitoring response to treatment and disease progression of metastatic breast cancer using PET-CT from the previous meeting.
9. AOB, Summary and next steps
The Chair outlined next steps following the meeting, thanked the committee for their contributions, summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, the Chair brought the meeting to a close.

Date of next meeting: 16/07/2025

Location of next meeting: Virtual